Human Peripheral Blood Mononuclear Cells (hPBMC), Cryopreserved, 10 million
Human Peripheral Blood Mononuclear Cells (hPBMC), Cryopreserved, 10 million
Cryopreserved ampule of Human Peripheral Blood Mononuclear Cells (hPBMC) containing ≥ 10 million cells.
Quantities of this part code may be limited, the following part code CC-2704 is recommended as an equivalent alternative.
Select Size
You May Also Need...
Product Overview
Mononuclear cell (MNC) rich cells from leukapheresis are depleted of RBCs and platelets. MNC pools contain, on average, 50% T cells, 20% monocytes, 10% B cells, 10% NK cells and may contain up to 5% granulocytes. Cells are cryopreserved in Lonza cryopreservation media. Count and viability is determined using AO/PI. Cells are collected from healthy donors following IRB protocols.
Manufactured by AllCells®
Request More InfoBenefits
- Test negative for mycoplasma, bacteria, yeast, and fungi
- HIV-1, Hepatitis B and Hepatitis C are not detected for all donors and/or cell lots
- Certificate of Analysis (CoA) is provided for each cell lot purchased
Applications
- ELISPOT
- Proliferation assays
- Immunogenicity assays
- Cell therapy process development
- Humanized mice
- Biomarker discovery
Storage and Content
- 1 x Cryopreserved ampule of Human Peripheral Blood Mononuclear Cells (hPBMC) containing ≥ 10 million cells
SDS, CoA, and Instructions
Safety Data Sheets (SDS)
Choose a language to view the SDS.
Certificate of Analysis (CoA)
Please enter Lot Number, including all zeros, located on the product label and please take into account that it is case sensitive.
Educational Material
Brochures, White Papers etc.
-
Blood and Immune Cells
Fueling your next discovery with unmatched cell and donor variety -
An Innovative, Highly Efficient Method for Transfecting Large Quantities of Primary Human T-cells
A strong need exists for improved cancer treatment options. Lonza's approach relies on genetically modified, patient-derived cells like T-cells or natural killer cells which express chimeric antigen receptors (CAR) targeting cancer cells. -
A Non-Viral Method for Modifying and Expanding Primary T Cells
Learn how Lonza’s Cocoon® Platform, 4D-Nucleofector® LV Unit and X-VIVO® 15 Medium are integrated to enable non-viral genetic modification and subsequent expansion of primary T cells in a functionally-closed, automated workflow. -
Procedure for thawing Poietics™ cells